Aldeyra Therapeutics ALDX Stock
Aldeyra Therapeutics Price Chart
Aldeyra Therapeutics ALDX Financial and Trading Overview
| Aldeyra Therapeutics stock price | 1.86 USD |
| Previous Close | 1.75 USD |
| Open | 1.74 USD |
| Bid | 1.24 USD x 200 |
| Ask | 2.08 USD x 200 |
| Day's Range | 1.62 - 1.74 USD |
| 52 Week Range | 1.07 - 6.18 USD |
| Volume | 677.66K USD |
| Avg. Volume | 3.08M USD |
| Market Cap | 100.13M USD |
| Beta (5Y Monthly) | 1.149 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.45 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.6 USD |
ALDX Valuation Measures
| Enterprise Value | 50.64M USD |
| Trailing P/E | N/A |
| Forward P/E | -9.222221 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 2.3748212 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -1.801 |
Trading Information
Aldeyra Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.149 |
| 52-Week Change | -17.45% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 6.18 USD |
| 52 Week Low | 1.07 USD |
| 50-Day Moving Average | 1.7 USD |
| 200-Day Moving Average | 4.24 USD |
ALDX Share Statistics
| Avg. Volume (3 month) | 3.08M USD |
| Avg. Daily Volume (10-Days) | 968.47K USD |
| Shares Outstanding | 60.32M |
| Float | 52.93M |
| Short Ratio | 7.01 |
| % Held by Insiders | 3.18% |
| % Held by Institutions | 62.79% |
| Shares Short | 7.58M |
| Short % of Float | 12.97% |
| Short % of Shares Outstanding | 12.57% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -22.21% |
| Return on Equity (ttm) | -51.76% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -28126984 USD |
| Net Income Avi to Common (ttm) | -27369780 USD |
| Diluted EPS (ttm) | -0.45 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 65M USD |
| Total Cash Per Share (mrq) | 1.08 USD |
| Total Debt (mrq) | 15.51M USD |
| Total Debt/Equity (mrq) | 36.8 USD |
| Current Ratio (mrq) | 2.724 |
| Book Value Per Share (mrq) | 0.699 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -25986072 USD |
| Levered Free Cash Flow (ttm) | -19602224 USD |
Profile of Aldeyra Therapeutics
| Country | United States |
| State | MA |
| City | Lexington |
| Address | 131 Hartwell Avenue |
| ZIP | 02421 |
| Phone | 781 761 4904 |
| Website | https://www.aldeyra.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 7 |
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Q&A For Aldeyra Therapeutics Stock
What is a current ALDX stock price?
Aldeyra Therapeutics ALDX stock price today per share is 1.86 USD.
How to purchase Aldeyra Therapeutics stock?
You can buy ALDX shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Aldeyra Therapeutics?
The stock symbol or ticker of Aldeyra Therapeutics is ALDX.
Which industry does the Aldeyra Therapeutics company belong to?
The Aldeyra Therapeutics industry is Biotechnology.
How many shares does Aldeyra Therapeutics have in circulation?
The max supply of Aldeyra Therapeutics shares is 60.32M.
What is Aldeyra Therapeutics Price to Earnings Ratio (PE Ratio)?
Aldeyra Therapeutics PE Ratio is now.
What was Aldeyra Therapeutics earnings per share over the trailing 12 months (TTM)?
Aldeyra Therapeutics EPS is -0.45 USD over the trailing 12 months.
Which sector does the Aldeyra Therapeutics company belong to?
The Aldeyra Therapeutics sector is Healthcare.
Aldeyra Therapeutics ALDX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Capital Market Composite RCMP | 148.96 USD — |
-1.84
|
— — | 148.23 USD — | 151.02 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
| US Tech Composite Total Return XCMP | 33104.2 USD — |
-0.89
|
— — | 32999.64 USD — | 33445.55 USD — | — - | — — |
- {{ link.label }} {{link}}